Helicos BioSciences, a developer of genetic analysis technologies for the research, drug discovery and clinical diagnostics markets, filed for an IPO Wednesday. UBS is the sole book runner on the deal. Terms and timing have not yet been announced.
Helicos BioSciences, a developer of genetic analysis technologies for the research, drug discovery and clinical diagnostics markets, filed for an IPO Wednesday. UBS is the sole book runner on the deal. Terms and timing have not yet been announced.